Terms ending in 2040
Every in-force patent on Codexis, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,427,813 | Human Alpha-Galactosidase Variants In force · High confidence | Crosswalk Therapeutics, Inc. | In force | High confidence | |
| US 11,795,445 | Engineered Phosphopentomutase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,018,295 | Engineered DNA Polymerase Variants In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,215,368 | Engineered Imine Reductases and Methods for the Reductive Amination of Ketone and Amine Compounds In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,473,077 | Engineered Tyrosine Ammonia Lyase In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,012,620 | Peroxidase Activity Towards 10-Acetyl-3,7-Dihydroxyphenoxazine In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,540,314 | Peroxidase Activity Towards 10-Acetyl-3,7-Dihydroxyphenoxazine In force · Medium confidence | Codexis, Inc. | In force | Medium confidence | |
| US 12,680,091 | Engineered Lipase Variants In force · High confidence | Codexis, Inc. and Societe des Produits Nestle S.A. | In force | High confidence | |
| US 12,286,653 | Carboxyesterase Polypeptides for Amide Coupling In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,497,605 | Engineered Acid Alpha-Glucosidase Variants In force · High confidence | Crosswalk Therapeutics, Inc. | In force | High confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
8 of these are in force and held by Codexis, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.